Chardan lowered the firm’s price target on Crispr Therapeutics (CRSP) to $74 from $82 and keeps a Buy rating on the shares. The firm updated the company’s model post the Q3 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Cathie Wood Doubles Down on This AI Stock, Cuts GitLab (GTLB) Again
- Crispr Therapeutics AG Faces Stock Price Slide
- Cathie Wood Buys Nvidia, ACHR and Crypto Stocks, Offloads AMD, EXAS
- Citizens JMP healthcare analysts hold an analyst/industry conference
- Crispr Therapeutics rumor highlighted in Betaville blog